167 related articles for article (PubMed ID: 28928878)
1. Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) After Initial TUR-BT: Comparative Analyses with Noninvasive Low-Grade Papillary Urothelial Carcinoma (LGPUC).
Kim JK; Moon KC; Jeong CW; Kwak C; Kim HH; Ku JH
J Cancer; 2017; 8(15):2885-2891. PubMed ID: 28928878
[No Abstract] [Full Text] [Related]
2. Evaluation of MUC1 and P53 expressions in noninvasive papillary urothelial neoplasms of bladder, their relationship with tumor grade and role in the differential diagnosis.
Kaymaz E; Ozer E; Unverdi H; Hucumenoglu S
Indian J Pathol Microbiol; 2017; 60(4):510-514. PubMed ID: 29323063
[TBL] [Abstract][Full Text] [Related]
3. Expression of MUC1 (Ma695) in noninvasive papillary urothelial neoplasm according to the 2004 World Health Organization classification of the noninvasive urothelial neoplasm. An immunologic tool for the pathologist?
Garbar C; Mascaux C
Anal Quant Cytol Histol; 2011 Oct; 33(5):277-82. PubMed ID: 22611755
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study on expression and clinical significance of PHH3, Ki67 and P53 in bladder exophytic papillary urothelial neoplasms.
Qi G; Liu J; Tao S; Fan W; Zheng H; Wang M; Yang H; Liu Y; Liu H; Zhou F
PeerJ; 2023; 11():e15675. PubMed ID: 37456895
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth.
Maxwell JP; Wang C; Wiebe N; Yilmaz A; Trpkov K
Diagn Pathol; 2015 Mar; 10():3. PubMed ID: 25886613
[TBL] [Abstract][Full Text] [Related]
6. Bladder papillary urothelial neoplasm of low malignant potential in Chinese: a clinical and pathological analysis.
Zhang XK; Wang YY; Chen JW; Qin T
Int J Clin Exp Pathol; 2015; 8(5):5549-55. PubMed ID: 26191263
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer.
Jones TD; Cheng L
Urol Oncol; 2021 May; 39(5):286-290. PubMed ID: 35550107
[TBL] [Abstract][Full Text] [Related]
8. The 1973 WHO Classification is more suitable than the 2004 WHO Classification for predicting prognosis in non-muscle-invasive bladder cancer.
Chen Z; Ding W; Xu K; Tan J; Sun C; Gou Y; Tong S; Xia G; Fang Z; Ding Q
PLoS One; 2012; 7(10):e47199. PubMed ID: 23082147
[TBL] [Abstract][Full Text] [Related]
9. Reappraisal of the papillary urothelial neoplasm of low malignant potential (PUNLMP).
Jones TD; Cheng L
Histopathology; 2020 Oct; 77(4):525-535. PubMed ID: 32562556
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological analysis of recurrence and progression of low-grade papillary urothelial carcinoma of the urinary bladder: Predicting the outcome.
Bahmad HF; Lopez O; Moreno JCA; Lopez K; Malik F; Salami A; Nieder AM; Omarzai Y; Poppiti RJ
Ann Diagn Pathol; 2022 Dec; 61():152030. PubMed ID: 36055007
[TBL] [Abstract][Full Text] [Related]
11. Papillary urothelial neoplasm of low malignant potential: reliability of diagnosis and outcome.
Campbell PA; Conrad RJ; Campbell CM; Nicol DL; MacTaggart P
BJU Int; 2004 Jun; 93(9):1228-31. PubMed ID: 15180612
[TBL] [Abstract][Full Text] [Related]
12. Cytologic diagnosis of low-grade papillary urothelial neoplasms (low malignant potential and low-grade carcinoma) in the context of the 1998 WHO/ISUP classification.
Whisnant RE; Bastacky SI; Ohori NP
Diagn Cytopathol; 2003 Apr; 28(4):186-90. PubMed ID: 12672093
[TBL] [Abstract][Full Text] [Related]
13. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.
Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A
J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286
[TBL] [Abstract][Full Text] [Related]
14. Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts.
Jones TD; Cheng L
J Urol; 2006 Jun; 175(6):1995-2003. PubMed ID: 16697785
[TBL] [Abstract][Full Text] [Related]
15. Bladder cancer recurrence in papillary urothelial neoplasm of low malignant potential (PUNLMP) compared to G1 WHO 1999: a population-based study.
Bobjer J; Hagberg O; Aljabery F; Gårdmark T; Jahnson S; Jerlström T; Sherif A; Simoulis A; Ströck V; Häggström C; Holmberg L; Liedberg F
Scand J Urol; 2022 Feb; 56(1):14-18. PubMed ID: 34623216
[TBL] [Abstract][Full Text] [Related]
16. The Association of A Number of Predictive Factors for The Recurrence of Papillary Urothelial Neoplasm of Low Malignant Potential: Prognostic Analysis From Multiple Academic Centers.
Kim KH; Lee SH; Kim SI; Chung BH; Koo KC; Cho JS; Bang WJ; Park JY; Hong SJ
Urol J; 2019 Dec; 16(6):558-562. PubMed ID: 30882164
[TBL] [Abstract][Full Text] [Related]
17. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
[TBL] [Abstract][Full Text] [Related]
18. Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered grading system) on reproducibility.
Tuna B; Yörükoglu K; Düzcan E; Sen S; Nese N; Sarsık B; Akder A; Sayhan S; Mungan U; Kirkali Z
Virchows Arch; 2011 Jun; 458(6):659-64. PubMed ID: 21484429
[TBL] [Abstract][Full Text] [Related]
19. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy.
Holmäng S; Andius P; Hedelin H; Wester K; Busch C; Johansson SL
J Urol; 2001 Apr; 165(4):1124-8; discussion 1128-30. PubMed ID: 11257652
[TBL] [Abstract][Full Text] [Related]
20. The effects of the current World Health Organization/International Society of Urologic Pathologists bladder neoplasm classification system on urine cytology results.
Curry JL; Wojcik EM
Cancer; 2002 Jun; 96(3):140-5. PubMed ID: 12115301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
